Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp, has reported several significant stock transactions in a recent SEC filing. The transactions include the acquisition of 11,881 shares at a price of $12.14 each on October 1, 2026, and additional sales of shares on October 5, 2026. These actions are part of a Rule 10b5-1 trading plan established by Rubinstein in November 2025.
This update is particularly noteworthy as it reflects Rubinstein's ongoing engagement with the company's stock and her confidence in its future performance. The life sciences industry, particularly in the biological products sector, is witnessing a trend of active trading among executives, which may influence market perceptions and investor confidence.
Background
Adaptive Biotechnologies Corp, identified by the Central Index Key (CIK) 0001478320, is a company based in Seattle, Washington, focused on developing innovative biological products. The firm operates within the Biological Products (No Diagnostic Substances) sector, classified under SIC code 2836. The company has been publicly traded under the ticker symbol ADPT.
What the Filing Says
According to the filing, Rubinstein executed multiple transactions involving common stock. On October 1, 2026, she acquired 11,881 shares at $12.14 each, and on October 5, 2026, she sold 6,699 shares at an average price of $28.82. The filing states, "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025." This plan allows executives to sell shares systematically while avoiding accusations of insider trading.
Impact
The reported transactions may have implications for investors and analysts monitoring Adaptive Biotechnologies. Rubinstein's stock activity could signal her belief in the company's growth potential, which may influence shareholder sentiment and market dynamics. Other executives in the life sciences sector may also be encouraged to engage in similar trading strategies, reflecting a broader trend of transparency in stock ownership.
What's Next
The filing does not say what happens next.